BR112016026773A2 - domínios variáveis de imunoglobulina aperfeiçoados - Google Patents

domínios variáveis de imunoglobulina aperfeiçoados

Info

Publication number
BR112016026773A2
BR112016026773A2 BR112016026773A BR112016026773A BR112016026773A2 BR 112016026773 A2 BR112016026773 A2 BR 112016026773A2 BR 112016026773 A BR112016026773 A BR 112016026773A BR 112016026773 A BR112016026773 A BR 112016026773A BR 112016026773 A2 BR112016026773 A2 BR 112016026773A2
Authority
BR
Brazil
Prior art keywords
amino acid
acid residue
variable domains
immunoglobulin variable
improved immunoglobulin
Prior art date
Application number
BR112016026773A
Other languages
English (en)
Portuguese (pt)
Inventor
Boutton Carlo
Buyse Marie-Ange
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Priority to BR122018009619-5A priority Critical patent/BR122018009619B1/pt
Publication of BR112016026773A2 publication Critical patent/BR112016026773A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112016026773A 2014-05-16 2015-05-13 domínios variáveis de imunoglobulina aperfeiçoados BR112016026773A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201461014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16
PCT/EP2015/060643 WO2015173325A2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains

Publications (1)

Publication Number Publication Date
BR112016026773A2 true BR112016026773A2 (pt) 2017-12-12

Family

ID=91193230

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016026773A BR112016026773A2 (pt) 2014-05-16 2015-05-13 domínios variáveis de imunoglobulina aperfeiçoados
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados

Country Status (25)

Country Link
US (10) US12180268B2 (enExample)
EP (4) EP3143042B1 (enExample)
JP (6) JP7325928B2 (enExample)
KR (5) KR102769509B1 (enExample)
CN (3) CN109053885A (enExample)
AU (6) AU2015261536B2 (enExample)
BR (2) BR112016026773A2 (enExample)
CA (2) CA3175002A1 (enExample)
DK (2) DK3143042T3 (enExample)
ES (2) ES2912069T3 (enExample)
HR (2) HRP20200966T1 (enExample)
HU (2) HUE050007T2 (enExample)
IL (6) IL311293B2 (enExample)
LT (2) LT3248986T (enExample)
MX (4) MX383560B (enExample)
NZ (1) NZ726448A (enExample)
PH (1) PH12016502282B1 (enExample)
PL (2) PL3143042T3 (enExample)
PT (2) PT3248986T (enExample)
RS (2) RS60717B1 (enExample)
RU (1) RU2746738C2 (enExample)
SG (3) SG10201810124PA (enExample)
SI (2) SI3248986T1 (enExample)
WO (1) WO2015173325A2 (enExample)
ZA (5) ZA201607587B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PL2723769T5 (pl) 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
SG10201810124PA (en) * 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
CN114478753A (zh) 2015-01-21 2022-05-13 英伊布里克斯公司 非免疫原性单结构域抗体
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
EP3374392B1 (en) 2015-11-13 2021-11-24 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CA3005488A1 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
EP3414268A1 (en) 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
ES2926014T3 (es) 2016-06-23 2022-10-21 Ablynx Nv Ensayos farmacocinéticos mejorados para dominios variables individuales de inmunoglobulina
IL266506B2 (en) 2016-11-16 2025-05-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
RU2765384C2 (ru) 2016-12-07 2022-01-28 Аблинкс Нв Улучшенные одиночные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
DK3571225T3 (da) 2017-01-17 2024-11-04 Ablynx Nv Forbedrede serumalbuminbindere
BR112019014600A2 (pt) 2017-01-17 2020-02-18 Ablynx N.V. Ligantes de albumina sérica melhorados
KR102752550B1 (ko) 2017-06-02 2025-01-10 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
EP3655436B1 (en) 2017-07-19 2025-10-15 Vib Vzw Serum albumin binding agents
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
CN114980923A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
MY208649A (en) 2019-12-09 2025-05-22 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
JP2023514654A (ja) 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ２のアロステリック調節因子
US20230136595A1 (en) 2020-03-30 2023-05-04 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US20230272094A1 (en) * 2020-08-05 2023-08-31 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
KR20230074527A (ko) * 2020-09-25 2023-05-30 아블린쓰 엔.브이. Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
PH12023500009A1 (en) 2020-12-18 2024-03-11 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
EP4262985A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN117043184A (zh) * 2021-04-01 2023-11-10 南京再明医药有限公司 抗人血清白蛋白（hsa）的纳米抗体及其应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4435002A4 (en) * 2021-11-29 2025-03-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. MODIFIED PROTEIN OR POLYPEPTIDE
JP2024546916A (ja) 2021-12-17 2024-12-26 アブリンクス エン．ヴェー． ＴＣＲαβ、ＣＤ３３及びＣＤ１２３を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
IL316708A (en) 2022-05-18 2024-12-01 Vib Vzw Cerbevirus S2 spike subunit binding
AU2023285094A1 (en) 2022-06-08 2025-01-23 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023290487A1 (en) 2022-06-14 2025-01-30 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4638502A2 (en) 2022-12-21 2025-10-29 Genzyme Corporation Anti-pd-1×4-1bb binding proteins
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
IL322564A (en) 2023-02-10 2025-10-01 Amunix Pharmaceuticals Inc Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
AU2024273077A1 (en) 2023-05-17 2025-11-13 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AR133108A1 (es) 2023-06-29 2025-08-27 Odyssey Therapeutics Inc Proteínas de unión a antígeno anti-trailr2 y sus usos
TW202517676A (zh) 2023-07-05 2025-05-01 比利時商艾伯霖克斯公司 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US4996206A (en) 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
KR20010034512A (ko) 1998-02-19 2001-04-25 베렌슨, 론 림프구 활성화 조절을 위한 조성물 및 그 방법
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2002360243A1 (en) 2001-07-26 2003-05-06 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­ｉｌ­1ｒ1 단일 도메인 항체 및 치료적 용도
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
AU2006321364B2 (en) 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009000099A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
AU2009231439A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
MX2010012518A (es) 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110200525A1 (en) 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
AR076796A1 (es) 2009-05-28 2011-07-06 Glaxo Group Ltd Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP2563814A1 (en) 2010-04-30 2013-03-06 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
PL2723769T5 (pl) * 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
MY167125A (en) * 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
KR102762747B1 (ko) * 2011-10-17 2025-02-05 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
HUE042531T2 (hu) 2012-01-31 2019-07-29 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
JP2015531350A (ja) * 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
SG10201810124PA (en) * 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
NO2768984T3 (enExample) 2015-11-12 2018-06-09
WO2017081265A1 (en) 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
EP3374392B1 (en) 2015-11-13 2021-11-24 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
BR112019014600A2 (pt) 2017-01-17 2020-02-18 Ablynx N.V. Ligantes de albumina sérica melhorados
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Also Published As

Publication number Publication date
IL295534B1 (en) 2024-11-01
ES2912069T3 (es) 2022-05-24
KR20230053002A (ko) 2023-04-20
ZA202004759B (en) 2022-08-31
JP2017518072A (ja) 2017-07-06
IL311293B2 (en) 2025-07-01
US20220135657A9 (en) 2022-05-05
US20220251183A1 (en) 2022-08-11
US11312765B2 (en) 2022-04-26
MX383560B (es) 2025-03-14
US20210261653A1 (en) 2021-08-26
SG10201810124PA (en) 2018-12-28
AU2020202855B2 (en) 2022-12-08
HRP20220400T1 (hr) 2022-05-27
AU2020202855A1 (en) 2020-05-21
AU2020202570B2 (en) 2022-12-08
KR20230054503A (ko) 2023-04-24
IL281755B2 (en) 2023-05-01
PL3143042T3 (pl) 2020-11-16
IL259972A (en) 2018-07-31
US20220119512A1 (en) 2022-04-21
JP2021130681A (ja) 2021-09-09
DK3143042T3 (da) 2020-08-31
LT3248986T (lt) 2022-03-25
KR102769509B1 (ko) 2025-02-17
RS63085B1 (sr) 2022-04-29
IL248636A0 (en) 2017-01-31
KR20230145503A (ko) 2023-10-17
CA2948076A1 (en) 2015-11-19
ZA202100742B (en) 2022-09-28
MX2023010731A (es) 2023-09-20
JP2024069377A (ja) 2024-05-21
IL299282A (en) 2023-02-01
DK3248986T3 (da) 2022-04-04
IL281755B1 (en) 2023-01-01
RU2746738C2 (ru) 2021-04-20
PL3248986T3 (pl) 2022-05-16
RU2016149463A (ru) 2018-06-19
US11485778B2 (en) 2022-11-01
US11312764B2 (en) 2022-04-26
KR20170002645A (ko) 2017-01-06
SI3248986T1 (sl) 2022-04-29
US20200231662A1 (en) 2020-07-23
IL259972B (en) 2021-04-29
CN106661100A (zh) 2017-05-10
EP3248986A2 (en) 2017-11-29
AU2015261536A1 (en) 2016-11-17
PH12016502282A1 (en) 2017-02-13
CN109053885A (zh) 2018-12-21
US11319364B2 (en) 2022-05-03
CA3175002A1 (en) 2015-11-19
US20170121399A1 (en) 2017-05-04
KR20180091115A (ko) 2018-08-14
US12180268B2 (en) 2024-12-31
RS60717B1 (sr) 2020-09-30
EP3693386A1 (en) 2020-08-12
IL281755A (en) 2021-05-31
AU2018204226A1 (en) 2018-07-05
US11708404B2 (en) 2023-07-25
ZA201607587B (en) 2022-05-25
AU2020202570A1 (en) 2020-05-07
AU2022279374A1 (en) 2023-01-19
JP2018162297A (ja) 2018-10-18
SG10201805288QA (en) 2018-07-30
US20210269514A1 (en) 2021-09-02
KR102827683B1 (ko) 2025-06-30
EP3143042A2 (en) 2017-03-22
IL299282B2 (en) 2024-09-01
WO2015173325A8 (en) 2016-12-29
IL295534B2 (en) 2025-03-01
JP2024041939A (ja) 2024-03-27
WO2015173325A3 (en) 2016-02-18
BR122018009619B1 (pt) 2024-01-02
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
JP7471987B2 (ja) 2024-04-22
LT3143042T (lt) 2020-07-27
IL248636B2 (en) 2023-04-01
IL299282B1 (en) 2024-05-01
MX2018007581A (es) 2020-11-12
SI3143042T1 (sl) 2020-08-31
PT3143042T (pt) 2020-09-01
RU2016149463A3 (enExample) 2018-07-04
IL248636B (en) 2022-12-01
RU2018120744A (ru) 2018-11-15
US20210087261A1 (en) 2021-03-25
EP3702369A1 (en) 2020-09-02
RU2018120744A3 (enExample) 2022-01-28
EP3248986A3 (en) 2017-12-20
JP7325928B2 (ja) 2023-08-15
WO2015173325A2 (en) 2015-11-19
ES2815572T3 (es) 2021-03-30
NZ726448A (en) 2023-02-24
US20220332807A1 (en) 2022-10-20
HUE058008T2 (hu) 2022-06-28
CN113717280A (zh) 2021-11-30
RU2021107470A (ru) 2021-05-17
PH12016502282B1 (en) 2024-05-22
JP7454525B2 (ja) 2024-03-22
HUE050007T2 (hu) 2020-11-30
ZA202004757B (en) 2022-08-31
PT3248986T (pt) 2022-04-05
US11485777B2 (en) 2022-11-01
HRP20200966T1 (hr) 2020-10-16
US20220332806A1 (en) 2022-10-20
IL311293B1 (en) 2025-03-01
MX2016014926A (es) 2017-05-09
US11220539B2 (en) 2022-01-11
EP3143042B1 (en) 2020-06-10
EP3248986B1 (en) 2022-01-26
JP2021006563A (ja) 2021-01-21
ZA202004758B (en) 2022-08-31
JP7098439B2 (ja) 2022-07-11
SG11201609162SA (en) 2016-12-29
MX2021007020A (es) 2021-08-05
US20210269515A1 (en) 2021-09-02
IL295534A (en) 2022-10-01
IL311293A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
BR112016026773A2 (pt) domínios variáveis de imunoglobulina aperfeiçoados
BR112017009467A2 (pt) composição de limpeza
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112017003582A2 (pt) anticorpos, composições e usos
BR112017009623A2 (pt) composição de limpeza
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
BR112017022073A2 (pt) método para purificação de proteína
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MX2017016590A (es) Dominios variables simples de inmunoglobulina contra proteina f de rsv.
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
BR112012013581A2 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2
EP3442559C0 (en) BMP-7 DERIVED PEPTIDES FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS
MX2016010431A (es) Composiciones para la prevencion y/o el tratamiento de patologias relacionadas con alfa-glucosidasa.
BR112018074874A2 (pt) composição cosmética antissinais, uso da composição, método de tratamento antissinais e dispositivo de aplicação
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
EP3581589A4 (en) HYBRID PEPTIDE, HYBRID PEPTIDE SET, COMPOSITION, USES OF HYBRID PEPTIDE, METHOD OF INDUCTION OF AN IMMUNE RESPONSE AND KITS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]